{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:30:33Z","timestamp":1769729433743,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ad.2016.07.018","type":"journal-article","created":{"date-parts":[[2016,10,8]],"date-time":"2016-10-08T23:30:45Z","timestamp":1475969445000},"page":"423-431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Omalizumab en el tratamiento de la urticaria cr\u00f3nica inducible"],"prefix":"10.1016","volume":"108","author":[{"given":"P.","family":"Chicharro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"de Argila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2016.07.018_bib0275","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ad.2013.06.002","article-title":"Omalizumab en el tratamiento de la urticaria cr\u00f3nica","volume":"105","author":"Franc\u00e9s","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2016.07.018_bib0280","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1476-7961-9-2","article-title":"Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab","volume":"9","author":"Saavedra","year":"2011","journal-title":"Clin Mol Allergy."},{"key":"10.1016\/j.ad.2016.07.018_bib0285","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","article-title":"The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis, and management of urticaria: The 2013 revision and update","volume":"69","author":"Zuberbier","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.ad.2016.07.018_bib0290","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","article-title":"American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphilaxis","volume":"120","author":"Cox","year":"2007","journal-title":"J Allergy Clin Inmmunol."},{"key":"10.1016\/j.ad.2016.07.018_bib0295","first-page":"627","article-title":"Urticaria caused by cold: 104 cases","volume":"123","author":"Koeppel","year":"1996","journal-title":"Ann Dermatol Venereol."},{"key":"10.1016\/j.ad.2016.07.018_bib0300","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1365-2133.2005.06757.x","article-title":"Cold urticaria; disease course and outcome--An investigation of 85 patients before and after therapy","volume":"153","author":"Buss","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2016.07.018_bib0305","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jaci.2006.04.003","article-title":"Successful treatment of cold-induced urticaria\/anaphylaxis with anti-IgE","volume":"117","author":"Boyce","year":"2006","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.ad.2016.07.018_bib0310","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000320233","article-title":"Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria","volume":"154","author":"Metz","year":"2011","journal-title":"Int Arch Allergy Immunol."},{"key":"10.1016\/j.ad.2016.07.018_bib0315","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000346284","article-title":"Treatment of severe cold contact urticaria with omalizumab: Case reports","volume":"4","author":"Brodsk\u00e1","year":"2012","journal-title":"Case Rep Dermatol."},{"key":"10.1016\/j.ad.2016.07.018_bib0320","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jaad.2012.10.026","article-title":"Effective treatment of idiopathic cold urticaria with omalizumab: Report of 3 cases","volume":"69","author":"Le Moing","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2016.07.018_bib0325","first-page":"303","article-title":"Treatment of severe cold-induced urticaria in a child with omalizumab","volume":"25","author":"Alba Mar\u00edn","year":"2015","journal-title":"J Investig Allergol Clin Immunol."},{"key":"10.1016\/j.ad.2016.07.018_bib0330","article-title":"Unique coexistence of cold and solar urticaria and its efficient treatment","volume":"174","author":"Zimmer","year":"2015","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2016.07.018_bib0335","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdermsci.2013.08.011","article-title":"Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis","volume":"73","author":"Metz","year":"2014","journal-title":"J Dermatol Sci."},{"key":"10.1016\/j.ad.2016.07.018_bib0340","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.anai.2013.12.005","article-title":"Real-life experiences with omalizumab for the treatment of chronic urticaria","volume":"112","author":"Sussman","year":"2014","journal-title":"Ann Allergy Asthma Immunol."},{"key":"10.1016\/j.ad.2016.07.018_bib0345","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0001-7310(05)73028-3","article-title":"Urticaria solar. Estudio de 20 casos","volume":"96","author":"Eguino","year":"2005","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2016.07.018_bib0350","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jaad.2008.08.020","article-title":"Solar urticaria","volume":"59","author":"Botto","year":"2008","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2016.07.018_bib0355","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/j.1398-9995.2008.01879.x","article-title":"Successful treatment of solar urticaria with anti-immunoglobulin E therapy","volume":"63","author":"G\u00fczelbey","year":"2008","journal-title":"Allergy."},{"key":"10.1016\/j.ad.2016.07.018_bib0360","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaci.2009.11.007","article-title":"Partial improvement of solar urticaria after omalizumab","volume":"125","author":"Waibel","year":"2010","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.ad.2016.07.018_bib0365","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-0781.2011.00624.x","article-title":"Failure of omalizumab (Xolair) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light","volume":"27","author":"Duchini","year":"2011","journal-title":"Photodermatol Photoimmunol Photomed."},{"key":"10.1016\/j.ad.2016.07.018_bib0370","first-page":"147","article-title":"Failure of omalizumab in ultraviolet-induced severe solar urticaria","volume":"33","author":"P\u00e9rez-Plaza","year":"2014","journal-title":"Immunology."},{"key":"10.1016\/j.ad.2016.07.018_bib0375","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/jdv.13001","article-title":"Three cases of solar urticaria successfully treated with omalizumab","volume":"30","author":"Baliu-Piqu\u00e9","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2016.07.018_bib0380","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/pai.12413","article-title":"Treatment with omalizumab in a 16-year-old Caucasian girl with refractory solar urticaria","volume":"26","author":"Arasi","year":"2015","journal-title":"Pediatr Allergy Immunol."},{"key":"10.1016\/j.ad.2016.07.018_bib0385","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/pai.12441","article-title":"Successful omalizumab treatment of severe solar urticaria in a 6-year-old child","volume":"26","author":"Levi","year":"2015","journal-title":"Pediatr Allergy Immunol."},{"key":"10.1016\/j.ad.2016.07.018_bib0390","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.anai.2015.12.023","article-title":"Effectiveness of omalizumab in severe solar urticaria","volume":"116","author":"De Dios-Vel\u00e1zquez","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.ad.2016.07.018_bib0395","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/jdv.12922","article-title":"Failure of omalizumab in the treatment of solar urticaria","volume":"30","author":"M\u00fcller","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2016.07.018_bib0400","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaad.2015.11.021","article-title":"Omalizumab in patients with severe and refractory solar urticaria: A phase ii multicentric study","volume":"74","author":"Aubin","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2016.07.018_bib0405","series-title":"Middleton's allergy: Principles and practice","first-page":"1071","article-title":"Urticaria and angioedema","author":"Kaplan","year":"2009"},{"key":"10.1016\/j.ad.2016.07.018_bib0410","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0190-9622(93)70273-V","article-title":"Diagnosis and incidence of delayed pressure urticaria in patients with chronic urticaria","volume":"29","author":"Barlow","year":"1993","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2016.07.018_bib0415","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1398-9995.2009.02188.x","article-title":"Efficacy of omalizumab in delayed pressure urticaria: A case report","volume":"65","author":"Bindslev-Jensen","year":"2010","journal-title":"Allergy."},{"key":"10.1016\/j.ad.2016.07.018_bib0420","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jaci.2010.05.047","article-title":"Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab","volume":"126","author":"Magerl","year":"2010","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.ad.2016.07.018_bib0425","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000336205","article-title":"Omalizumab for chronic urticaria: A case series and overview of the literature","volume":"4","author":"Ivyanskiy","year":"2012","journal-title":"Case Rep Dermatol."},{"key":"10.1016\/j.ad.2016.07.018_bib0430","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.aller.2012.11.001","article-title":"Successful treatment of severe delayed pressure angio-edema with omalizumab","volume":"42","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2014","journal-title":"Allergol Immunopathol (Madr)."},{"key":"10.1016\/j.ad.2016.07.018_bib0435","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2340\/00015555-2224","article-title":"Bullous delayed pressure urticaria responding to omalizumab","volume":"96","author":"M\u00fcller","year":"2016","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.ad.2016.07.018_bib0440","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/0394632015623795","article-title":"Effective treatment of different phenotypes of chronic urticaria with omalizumab: Case reports and review of literature","volume":"29","author":"Kasperska-Zajac","year":"2016","journal-title":"Int J Immunopathol Pharmacol."},{"key":"10.1016\/j.ad.2016.07.018_bib0445","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.anai.2015.10.009","article-title":"Successful treatment of occupational delayed pressure urticaria and angioedema with omalizumab","volume":"116","author":"Geller","year":"2016","journal-title":"Ann Allergy Asthma Immunol."},{"key":"10.1016\/j.ad.2016.07.018_bib0450","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1398-9995.2010.02409.x","article-title":"Antihistamine-resistant urticaria factitia succesfully treated with anti-immunoglobulin E therapy","volume":"65","author":"Krause","year":"2010","journal-title":"Allergy."},{"key":"10.1016\/j.ad.2016.07.018_bib0455","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.iac.2013.09.010","article-title":"Physical urticarias and cholinergic urticaria","volume":"34","author":"Abajian","year":"2014","journal-title":"Immunol Allergy Clin North Am."},{"key":"10.1016\/j.ad.2016.07.018_bib0460","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1398-9995.2009.02268.x","article-title":"Effective treatment of refractory severe heat urticaria with omalizumab","volume":"65","author":"Bullerkotte","year":"2010","journal-title":"Allergy."},{"key":"10.1016\/j.ad.2016.07.018_bib0465","first-page":"519","article-title":"Omalizumab treatment in 2 cases of refractory heat urticaria","volume":"23","author":"Carballada","year":"2013","journal-title":"J Investig Allergol Clin Immunol."},{"key":"10.1016\/j.ad.2016.07.018_bib0470","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2230.2012.04430.x","article-title":"Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema","volume":"38","author":"Pressler","year":"2013","journal-title":"Clin Exp Dermatol."},{"key":"10.1016\/j.ad.2016.07.018_bib0475","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2500\/aap.2009.30.3237","article-title":"A case of severe refractory chronic urticaria: A novel method for evaluation and treatment","volume":"30","author":"Otto","year":"2009","journal-title":"Allergy Asthma Proc."},{"key":"10.1016\/j.ad.2016.07.018_bib0480","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1398-9995.2007.01591.x","article-title":"Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy","volume":"63","author":"Metz","year":"2008","journal-title":"Allergy."},{"key":"10.1016\/j.ad.2016.07.018_bib0485","first-page":"148","article-title":"Failure of omalizumab in cholinergic urticaria","volume":"122","author":"Sabroe","year":"2010","journal-title":"Clin Exp Dermatol."},{"key":"10.1016\/j.ad.2016.07.018_bib0490","doi-asserted-by":"crossref","first-page":"AB28","DOI":"10.1016\/j.jaci.2012.12.783","article-title":"Successful treatment of refractory cholinergic urticaria with omalizumab in a pediatric patient","volume":"131","author":"Bantz","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.ad.2016.07.018_bib0495","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.4103\/0366-6999.157703","article-title":"Healing effects of omalizumab in a patient with cholinergic urticaria associated severe dyspeptic complaints","volume":"128","author":"Kutlu","year":"2015","journal-title":"Chin Med J (Engl)."},{"key":"10.1016\/j.ad.2016.07.018_bib0500","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaip.2015.12.017","article-title":"A case of aquagenic urticaria succesfully treated with omalizumab","volume":"4","author":"Rorie","year":"2016","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.ad.2016.07.018_bib0505","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jaci.2013.12.1076","article-title":"Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria control","volume":"133","author":"Weller","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.ad.2016.07.018_bib0510","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.ad.2015.05.009","article-title":"Adaptaci\u00f3n transcultural del cuestionario Urticaria Control Test del alem\u00e1n al castellano","volume":"106","author":"Garc\u00eda-D\u00edez","year":"2015","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2016.07.018_bib0515","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/j.1398-9995.2009.02177.x","article-title":"The definition and diagnostic testing of physical and cholinergic urticarias--EAACI\/GA2LEN\/EDF\/UNEV consensus panel recommendations","volume":"64","author":"Magerl","year":"2009","journal-title":"Allergy."},{"key":"10.1016\/j.ad.2016.07.018_bib0520","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/all.12884","article-title":"The definition, diagnostic testing and management of chronic inducible urticarias - Update and revision of the EAACI\/GA(2) LEN\/EDF\/UNEV 2009 consensus panel recommendations","volume":"71","author":"Magerl","year":"2016","journal-title":"Allergy."},{"key":"10.1016\/j.ad.2016.07.018_bib0525","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamadermatol.2013.8705","article-title":"Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria","volume":"150","author":"Metz","year":"2014","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2016.07.018_bib0530","unstructured":"Multicenter randomized, double-blind, placebo-controlled parallel clinical trial to assess efficacy and safety of omalizumab (Xolair\u00ae) in a new indication: Cholinergic urticaria. En: ClinicalTrials.gov (Internet). Bethesda (MD): National Library of Medicine (US); 2000 [consultado 20 Mar 2016]. Disponible en: http:\/\/clinicaltrials.gov\/show\/NCT02012387"},{"key":"10.1016\/j.ad.2016.07.018_bib0535","unstructured":"A two-center, double blind, placebo-controlled study in parallel design to assess the efficacy and safety of 150 and 300mg omalizumab in subjects with antihistamine-resistant cold contact urticaria (CCU). En: ClinicalTrials.gov (Internet). Bethesda (MD): National Library of Medicine (US); 2000 [consultado 20 Mar 2016]. Disponible en: http:\/\/clinicaltrials.gov\/show\/NCT01580592"},{"key":"10.1016\/j.ad.2016.07.018_bib0540","unstructured":"Double-blind, placebo-controlled 12-week, parallel-group study with a 6 weeks follow up period to demonstrate efficacy and safety of subcutaneous omalizumab in patients with urticaria factitia refractory to standard treatment. En: ClinicalTrials.gov (Internet). Bethesda (MD): National Library of Medicine (US); 2000 [consultado 20 Mar 2016]. Disponible en: http:\/\/clinicaltrials.gov\/show\/NCT02169115"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731016302861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731016302861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:05:54Z","timestamp":1757552754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731016302861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0001731016302861"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2016.07.018","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab en el tratamiento de la urticaria cr\u00f3nica inducible","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2016.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 AEDV. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}